Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction
(2020) In Military medicine 185(1). p.311-318- Abstract
INTRODUCTION: Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials. METHODS: To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, we integrate findings and mechanistic models from the DOD-sponsored "Systems Biology of PTSD Study" with previous data on these topics. RESULTS: Data implicate inter-linked dysregulations in metabolism,... (More)
INTRODUCTION: Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials. METHODS: To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, we integrate findings and mechanistic models from the DOD-sponsored "Systems Biology of PTSD Study" with previous data on these topics. RESULTS: Data implicate inter-linked dysregulations in metabolism, inflammation, mitochondrial function, and perhaps the gut microbiome in PTSD. Several inadequately tested targets of pharmacological intervention are proposed, including insulin sensitizers, lipid regulators, anti-inflammatories, and mitochondrial biogenesis modulators. CONCLUSIONS: Systemic pathologies that are intricately involved in brain functioning and behavior may not only contribute to somatic comorbidities in PTSD, but may represent novel targets for treating core psychiatric symptoms.
(Less)
- author
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Military medicine
- volume
- 185
- issue
- 1
- pages
- 8 pages
- publisher
- Association of Military Surgeons of the US
- external identifiers
-
- scopus:85079756639
- pmid:32074311
- ISSN
- 1930-613X
- DOI
- 10.1093/milmed/usz260
- language
- English
- LU publication?
- yes
- id
- dfd7586f-8723-4686-999c-61d5bda4df79
- date added to LUP
- 2020-03-18 13:32:39
- date last changed
- 2024-06-26 12:01:40
@article{dfd7586f-8723-4686-999c-61d5bda4df79, abstract = {{<p>INTRODUCTION: Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials. METHODS: To elucidate the potential involvement of metabolism, inflammation, and mitochondrial function in PTSD, we integrate findings and mechanistic models from the DOD-sponsored "Systems Biology of PTSD Study" with previous data on these topics. RESULTS: Data implicate inter-linked dysregulations in metabolism, inflammation, mitochondrial function, and perhaps the gut microbiome in PTSD. Several inadequately tested targets of pharmacological intervention are proposed, including insulin sensitizers, lipid regulators, anti-inflammatories, and mitochondrial biogenesis modulators. CONCLUSIONS: Systemic pathologies that are intricately involved in brain functioning and behavior may not only contribute to somatic comorbidities in PTSD, but may represent novel targets for treating core psychiatric symptoms.</p>}}, author = {{Bersani, F. Saverio and Mellon, Synthia H. and Lindqvist, Daniel and Kang, Jee In and Rampersaud, Ryan and Somvanshi, Pramod Rajaram and Doyle, Francis J. and Hammamieh, Rasha and Jett, Marti and Yehuda, Rachel and Marmar, Charles R. and Wolkowitz, Owen M.}}, issn = {{1930-613X}}, language = {{eng}}, number = {{1}}, pages = {{311--318}}, publisher = {{Association of Military Surgeons of the US}}, series = {{Military medicine}}, title = {{Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction}}, url = {{http://dx.doi.org/10.1093/milmed/usz260}}, doi = {{10.1093/milmed/usz260}}, volume = {{185}}, year = {{2020}}, }